New hope for Alzheimer's patients? Let's talk about this new drug (Donanemab).

If someone in your family, perhaps your beloved mother, father, or grandmother, is suffering from Alzheimer's Disease, we know how painful it can be. It is very sad to see your loved one's memory gradually disappear. However, in the midst of this difficult situation, we are talking about a piece of news that brings a little hope. This is not a complete cure for the disease, but it can be an important step forward.

What is this new news?

Recently, an advisory panel of the US Food and Drug Administration (FDA) unanimously gave the green light to a new Alzheimer's treatment. The name of the drug is donanemab . It is recommended for patients in the early stages of the disease. The approval of this advisory panel means that there is a high chance that the FDA will soon give full approval to this drug. This is really a big deal, because the arrival of a new treatment for a serious disease like Alzheimer's is a great hope.

How does Donanemab work?

Okay, now let's see how this drug works. This is a little complicated, but I'll explain it simply. Donanemab is a type of drug called a monoclonal antibody . Simply put, it's a special protein that's made in the lab to attack a specific target using parts of our own immune system. What is the target of this drug? It's amyloid plaques , which are thought to be a major cause of Alzheimer's disease. Just like rust builds up in our water pipes, these plaques build up between nerve cells in the brain and interfere with their function. What Donanemab does is identify these plaques and help remove them.

How effective is this medicine?

According to the results of clinical trials published last year, the treatment has been able to slow the rate of disease progression by several months . This was measured through tests that measured patients’ cognitive abilities (e.g., memory, problem-solving) and how well they performed tasks of daily living (e.g., driving, managing money). Some experts call these results modest or “moderate” results. This means that it is not expected to make a huge difference. But it is still a big deal to be able to slow the disease progression by several months, rather than letting it get worse without any treatment. As for the way the treatment is given, the drug is given to patients via a monthly infusion (infusion). Those who participated in the trials have been given this treatment for about a year and a half.

There are benefits as well as serious risks.

Like any powerful drug, donanemab has benefits as well as serious side effects and risks. It is important to understand both sides before making a decision. Despite all these considerations, the FDA advisory panel ultimately decided that the benefits of this drug outweigh its risks . That is, if given to the right patients, under proper supervision, the benefits are greater.

Is this the only new medicine available?

No. There is another drug that works in a similar way. It is called lecanemab . That drug also works by targeting platelets that accumulate in the brain. It received FDA approval in July 2023. Donanemab is another step in that journey. The world's leading Alzheimer's associations have high hopes for new treatments like this. They say, "The more approved treatments like this come out, the greater the chance of patients who qualify for them. Clear progress is being made in terms of treatment." Currently, millions of people around the world suffer from Alzheimer's disease. There is still no way to completely prevent or cure this disease. Therefore, drugs like donanemab are very important milestones in that long journey. Alzheimer's Disease, donanemab, brain disease, memory loss, dementia, new treatments, monoclonal antibody